Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARCUS W LEE

Allopathic & Osteopathic Physicians Family Medicine

NPI
1457364077
CMS profile
20974
Location
TULLAHOMA, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$20.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Gift $20.00 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $20.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARCUS W LEE

NPI 1457364077 · CMS profile ID 20974

Allopathic & Osteopathic Physicians / Family Medicine

TULLAHOMA, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1457364077?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARCUS W LEE, NPI 1457364077, CMS profile ID 20974. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1457364077?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MARCUS W LEE, NPI 1457364077, CMS profile ID 20974. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1457364077?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MARCUS W LEE, NPI 1457364077, CMS profile ID 20974, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1457364077?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $20.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $20.0006/03/2021 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833593793 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,069.95 90
PY2021 $20.00 1
PY2024 $351.93 19
PY2025 $413.66 22

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2022 Principal investigator $41,224.32 19
PY2021 Principal investigator $508,494.07 158
PY2020 Principal investigator $652,209.70 156
PY2019 Principal investigator $293,637.72 176

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

176 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan Inc. $11,818.20 12/31/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670122817
Principal investigator 1 Novo Nordisk AS $3.05 12/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706718041
Principal investigator 1 Novo Nordisk AS $7.40 12/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706718043
Principal investigator 1 Novo Nordisk AS $1,297.08 12/23/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 692447719
Principal investigator 1 Novo Nordisk AS $1,745.28 12/19/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 692447713
Principal investigator 1 Novo Nordisk AS $1,500.00 12/19/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 692447715
Principal investigator 1 Novo Nordisk AS $275.00 12/19/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 692447717
Principal investigator 1 Allergan Inc. $700.00 12/17/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670113397
Principal investigator 1 Allergan Inc. $6,312.75 12/13/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670110683
Principal investigator 1 AbbVie, Inc. $1,653.95 12/10/2019 Non-covered Recipient Entity
Trinity Clinical Research LLC
M16-100 No dispute reported 06/30/2026 647594487
Principal investigator 1 Novo Nordisk AS $2,688.66 12/03/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 692447711
Principal investigator 1 Novo Nordisk AS $6,242.40 12/03/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 692447721
Principal investigator 1 AbbVie, Inc. $4,356.53 11/27/2019 Non-covered Recipient Entity
Trinity Clinical Research LLC
M16-100 No dispute reported 06/30/2026 647594489
Principal investigator 1 Novo Nordisk AS $7.65 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717875
Principal investigator 1 Novo Nordisk AS $7.65 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717877
Principal investigator 1 Novo Nordisk AS $7.65 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717879
Principal investigator 1 Novo Nordisk AS $7.65 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717881
Principal investigator 1 Novo Nordisk AS $7.65 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717883
Principal investigator 1 Novo Nordisk AS $7.65 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717885
Principal investigator 1 Novo Nordisk AS $7.65 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717887
Principal investigator 1 Novo Nordisk AS $17.07 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717889
Principal investigator 1 Novo Nordisk AS $17.07 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717891
Principal investigator 1 Novo Nordisk AS $17.07 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717893
Principal investigator 1 Novo Nordisk AS $17.07 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717895
Principal investigator 1 Novo Nordisk AS $17.07 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717897
Principal investigator 1 Novo Nordisk AS $17.07 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717899
Principal investigator 1 Novo Nordisk AS $17.07 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717901
Principal investigator 1 Novo Nordisk AS $17.07 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717903
Principal investigator 1 Novo Nordisk AS $17.07 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717905
Principal investigator 1 Novo Nordisk AS $17.07 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717907
Principal investigator 1 Novo Nordisk AS $17.07 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717909
Principal investigator 1 Novo Nordisk AS $17.07 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717911
Principal investigator 1 Novo Nordisk AS $17.07 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717913
Principal investigator 1 Novo Nordisk AS $17.07 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717915
Principal investigator 1 Novo Nordisk AS $17.07 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717917
Principal investigator 1 Novo Nordisk AS $17.07 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717919
Principal investigator 1 Novo Nordisk AS $17.07 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717921
Principal investigator 1 Novo Nordisk AS $17.07 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717923
Principal investigator 1 Novo Nordisk AS $17.07 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717925
Principal investigator 1 Novo Nordisk AS $17.07 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717927
Principal investigator 1 Novo Nordisk AS $17.07 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717929
Principal investigator 1 Novo Nordisk AS $138.85 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717931
Principal investigator 1 Novo Nordisk AS $26.00 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717933
Principal investigator 1 Novo Nordisk AS $74.95 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717935
Principal investigator 1 Novo Nordisk AS $39.50 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717937
Principal investigator 1 Novo Nordisk AS $18.30 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717939
Principal investigator 1 Novo Nordisk AS $180.00 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717941
Principal investigator 1 Novo Nordisk AS $64.90 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717943
Principal investigator 1 Novo Nordisk AS $7.65 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706718009
Principal investigator 1 Novo Nordisk AS $7.65 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706718011
Principal investigator 1 Novo Nordisk AS $7.65 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706718013
Principal investigator 1 Novo Nordisk AS $7.65 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706718015
Principal investigator 1 Novo Nordisk AS $7.65 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706718017
Principal investigator 1 Novo Nordisk AS $7.65 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706718019
Principal investigator 1 Novo Nordisk AS $7.65 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706718021
Principal investigator 1 Novo Nordisk AS $7.65 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706718023
Principal investigator 1 Novo Nordisk AS $7.65 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706718025
Principal investigator 1 Novo Nordisk AS $7.65 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706718027
Principal investigator 1 Novo Nordisk AS $7.65 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706718029
Principal investigator 1 Novo Nordisk AS $7.65 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706718031
Principal investigator 1 Novo Nordisk AS $7.65 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706718033
Principal investigator 1 Novo Nordisk AS $7.65 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706718035
Principal investigator 1 Novo Nordisk AS $7.65 11/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706718037
Principal investigator 1 Novo Nordisk AS $7.65 11/20/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717945
Principal investigator 1 Novo Nordisk AS $7.65 11/20/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717947
Principal investigator 1 Novo Nordisk AS $7.65 11/20/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717949
Principal investigator 1 Novo Nordisk AS $7.65 11/20/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717951
Principal investigator 1 Novo Nordisk AS $7.65 11/20/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717953
Principal investigator 1 Novo Nordisk AS $7.65 11/20/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717955
Principal investigator 1 Novo Nordisk AS $7.65 11/20/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717957
Principal investigator 1 Novo Nordisk AS $7.65 11/20/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717959
Principal investigator 1 Novo Nordisk AS $7.65 11/20/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717961
Principal investigator 1 Novo Nordisk AS $7.65 11/20/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717963
Principal investigator 1 Novo Nordisk AS $7.65 11/20/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717965
Principal investigator 1 Novo Nordisk AS $7.65 11/20/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717967
Principal investigator 1 Novo Nordisk AS $7.65 11/20/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717969
Principal investigator 1 Novo Nordisk AS $7.65 11/20/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717971
Principal investigator 1 Novo Nordisk AS $7.65 11/20/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717973
Principal investigator 1 Novo Nordisk AS $7.65 11/20/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717975
Principal investigator 1 Novo Nordisk AS $7.65 11/20/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717977
Principal investigator 1 Novo Nordisk AS $7.65 11/20/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717979
Principal investigator 1 Novo Nordisk AS $7.65 11/20/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717981
Principal investigator 1 Novo Nordisk AS $7.65 11/20/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717983
Principal investigator 1 Novo Nordisk AS $7.65 11/20/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717985
Principal investigator 1 Novo Nordisk AS $7.65 11/20/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717987
Principal investigator 1 Novo Nordisk AS $48.12 11/20/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717989
Principal investigator 1 Novo Nordisk AS $27.00 11/20/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717991
Principal investigator 1 Novo Nordisk AS $180.00 11/20/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717993
Principal investigator 1 Novo Nordisk AS $7.95 11/20/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717995
Principal investigator 1 Novo Nordisk AS $1.68 11/20/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717997
Principal investigator 1 Novo Nordisk AS $14.70 11/20/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717999
Principal investigator 1 Novo Nordisk AS $90.00 11/20/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706718001
Principal investigator 1 Novo Nordisk AS $9.75 11/20/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706718003
Principal investigator 1 Novo Nordisk AS $14.70 11/20/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706718005
Principal investigator 1 Novo Nordisk AS $54.00 11/20/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706718007
Principal investigator 1 Allergan Inc. $6,953.05 11/13/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670096838
Principal investigator 1 Allergan Inc. $86.00 11/12/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670095365
Principal investigator 1 AbbVie, Inc. $2,011.21 10/30/2019 Non-covered Recipient Entity
Trinity Clinical Research LLC
M16-100 No dispute reported 06/30/2026 647594485
Principal investigator 1 Novo Nordisk AS $24.99 10/30/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717873
Principal investigator 1 Novo Nordisk AS $6,392.52 10/29/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 692447693
Principal investigator 1 Novo Nordisk AS $1,275.48 10/29/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 692447695
Principal investigator 1 Allergan Inc. $7,381.50 10/15/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670085709
Principal investigator 1 Novo Nordisk AS $1,539.00 09/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 692447701
Principal investigator 1 Novo Nordisk AS $1,828.98 09/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 692447709
Principal investigator 1 Allergan Inc. $6,312.75 09/18/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670076833
Principal investigator 1 AbbVie, Inc. $813.24 09/13/2019 Non-covered Recipient Entity
Trinity Clinical Research LLC
M16-100 No dispute reported 06/30/2026 647594483
Principal investigator 1 Novo Nordisk AS $5.30 09/06/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717851
Principal investigator 1 Novo Nordisk AS $14.70 09/06/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717853
Principal investigator 1 Novo Nordisk AS $2.40 09/06/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717855
Principal investigator 1 Novo Nordisk AS $270.00 09/06/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717857
Principal investigator 1 Novo Nordisk AS $10.60 09/06/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717859
Principal investigator 1 Novo Nordisk AS $2.24 09/06/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717861
Principal investigator 1 Novo Nordisk AS $19.60 09/06/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717863
Principal investigator 1 Novo Nordisk AS $120.00 09/06/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717865
Principal investigator 1 Novo Nordisk AS $13.00 09/06/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717867
Principal investigator 1 Novo Nordisk AS $19.60 09/06/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717869
Principal investigator 1 Novo Nordisk AS $72.00 09/06/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717871
Principal investigator 1 Allergan Inc. $86.00 09/05/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670073401
Principal investigator 1 Allergan Inc. $86.00 09/03/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670072215
Principal investigator 1 Novo Nordisk AS $1,329.48 08/30/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 692447699
Principal investigator 1 Novo Nordisk AS $476.00 08/30/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 692447707
Principal investigator 1 AbbVie, Inc. $1,067.82 08/16/2019 Non-covered Recipient Entity
Trinity Clinical Research LLC
M16-100 No dispute reported 06/30/2026 647594481
Principal investigator 1 Allergan Inc. $8,644.05 08/14/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670065511
Principal investigator 1 Novo Nordisk AS $1,340.28 07/30/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 692447697
Principal investigator 1 Novo Nordisk AS $2,500.00 07/30/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 692447703
Principal investigator 1 Novo Nordisk AS $1,000.00 07/30/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 692447705
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 07/16/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE IV, 12 WEEK, RANDOMISED, DOUBLE BLIND STUDY TO COMPARE SINGLE No dispute reported 06/30/2026 669959061
Principal investigator 1 AbbVie, Inc. $5,044.26 07/15/2019 Non-covered Recipient Entity
Trinity Clinical Research LLC
M16-100 No dispute reported 06/30/2026 647594479
Principal investigator 1 Allergan Inc. $800.00 07/15/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670056624
Principal investigator 1 Allergan Inc. $250.00 07/15/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670056629
Principal investigator 1 Allergan Inc. $10,812.90 07/15/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670057139
Principal investigator 1 Novo Nordisk AS $12.00 07/11/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717847
Principal investigator 1 Novo Nordisk AS $12.00 07/11/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717849
Principal investigator 1 Novo Nordisk AS $80.20 07/10/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717843
Principal investigator 1 Novo Nordisk AS $45.00 07/10/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717845
Principal investigator 1 PFIZER INC. $533.14 06/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671644979
Principal investigator 1 Novo Nordisk AS $2,801.52 06/25/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 692447691
Principal investigator 1 AbbVie, Inc. $5,114.63 06/20/2019 Non-covered Recipient Entity
Trinity Clinical Research LLC
M16-100 No dispute reported 06/30/2026 647594477
Principal investigator 1 Novo Nordisk AS $13.25 06/07/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717829
Principal investigator 1 Novo Nordisk AS $2.80 06/07/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717831
Principal investigator 1 Novo Nordisk AS $24.50 06/07/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717833
Principal investigator 1 Novo Nordisk AS $150.00 06/07/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717835
Principal investigator 1 Novo Nordisk AS $16.25 06/07/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717837
Principal investigator 1 Novo Nordisk AS $24.50 06/07/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717839
Principal investigator 1 Novo Nordisk AS $90.00 06/07/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717841
Principal investigator 1 Novo Nordisk AS $75.00 05/31/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706717827
Principal investigator 1 Novo Nordisk AS $607.00 05/29/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 706718039
Principal investigator 1 Allergan Inc. $8,644.05 05/28/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670048279
Principal investigator 1 Novo Nordisk AS $4,877.28 05/28/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 692447689
Principal investigator 1 AbbVie, Inc. $4,066.20 05/16/2019 Non-covered Recipient Entity
Trinity Clinical Research LLC
M16-100 No dispute reported 06/30/2026 647594475
Principal investigator 1 Allergan Inc. $12,609.35 04/25/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670041316
Principal investigator 1 Novo Nordisk AS $4,099.68 04/25/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 692447687
Principal investigator 1 AbbVie, Inc. $13,576.62 04/16/2019 Non-covered Recipient Entity
Trinity Clinical Research LLC
M16-100 No dispute reported 06/30/2026 647594473
Principal investigator 1 Novo Nordisk AS $24.99 04/04/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717825
Principal investigator 1 Allergan Inc. $9,410.70 03/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670033373
Principal investigator 1 Novo Nordisk AS $648.54 03/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 692447685
Principal investigator 1 AbbVie, Inc. $9,547.47 03/22/2019 Non-covered Recipient Entity
Trinity Clinical Research LLC
M16-100 No dispute reported 06/30/2026 647594469
Principal investigator 1 Novo Nordisk AS $3.66 03/18/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717821
Principal investigator 1 Novo Nordisk AS $12.98 03/18/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717823
Principal investigator 1 GlaxoSmithKline, LLC. $6,925.00 03/14/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE IV, 12 WEEK, RANDOMISED, DOUBLE BLIND STUDY TO COMPARE SINGLE No dispute reported 06/30/2026 669953803
Principal investigator 1 Allergan Inc. $10,084.25 02/28/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670027749
Principal investigator 1 Novo Nordisk AS $2,239.92 02/26/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 692447683
Principal investigator 1 GlaxoSmithKline, LLC. $718.13 02/21/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE IV, 12 WEEK, RANDOMISED, DOUBLE BLIND STUDY TO COMPARE SINGLE No dispute reported 06/30/2026 669953785
Principal investigator 1 GlaxoSmithKline, LLC. $185.00 02/14/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE IV, 12 WEEK, RANDOMISED, DOUBLE BLIND STUDY TO COMPARE SINGLE No dispute reported 06/30/2026 669962639
Principal investigator 1 PFIZER INC. $600.36 02/13/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671628743
Principal investigator 1 Novo Nordisk AS $1.70 02/08/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717819
Principal investigator 1 Allergan Inc. $8,306.80 02/05/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670021261
Principal investigator 1 GlaxoSmithKline, LLC. $4,278.00 01/24/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE IV, 12 WEEK, RANDOMISED, DOUBLE BLIND STUDY TO COMPARE SINGLE No dispute reported 06/30/2026 669953771
Principal investigator 1 AbbVie, Inc. $15,133.85 01/18/2019 Non-covered Recipient Entity
Trinity Clinical Research LLC
M16-100 No dispute reported 06/30/2026 647594471
Principal investigator 1 Novo Nordisk AS $3.66 01/18/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717815
Principal investigator 1 Novo Nordisk AS $12.98 01/18/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706717817
Principal investigator 1 GlaxoSmithKline, LLC. $18,525.00 01/17/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE IV, 12 WEEK, RANDOMISED, DOUBLE BLIND STUDY TO COMPARE SINGLE No dispute reported 06/30/2026 669953595
Principal investigator 1 PFIZER INC. $194.13 01/16/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671628947
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,567.76 01/15/2019 Non-covered Recipient Entity
Trinity Clinical Research Llc
A Multinational Randomised Double Blind Placebo Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg twice daily on the Incidence of Cardiovascular Death Myocardial Infarction or Stroke in Patients with Type 2 Diabetes No dispute reported 06/30/2026 684994179
Principal investigator 1 Allergan Inc. $9,383.15 01/03/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670014485
Principal investigator 1 GlaxoSmithKline, LLC. $24,464.00 01/03/2019 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
A PHASE IV, 12 WEEK, RANDOMISED, DOUBLE BLIND STUDY TO COMPARE SINGLE No dispute reported 06/30/2026 669953735